A Phase 1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of Multiple Ascending Dose (MAD) of PA1010 Tablets in Chinese Patients With Chronic Hepatitis B Infection
Latest Information Update: 06 Feb 2023
At a glance
- Drugs PA 1010 (Primary) ; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Zhejiang Palo Alto Pharmaceuticals
- 29 Jan 2023 Status changed from recruiting to completed.
- 28 Jun 2022 Planned End Date changed from 1 Mar 2022 to 1 Nov 2022.
- 28 Jun 2022 Planned primary completion date changed from 1 Feb 2022 to 1 Oct 2022.